Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.55 |
| ▸ | CTSK | P43235 | 4/20 | 0.55 |
| ▸ | CTSB | P07858 | 6/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002994 | 1.00 | CTSL (0.55) | CTSLCTSKCTSBCTSSTACR1 | |
| SCHEMBL31333314 | 0.86 | ALDH1A1 (0.60) | CTSLCTSKCTSB | |
| SCHEMBL21144825 | 0.82 | CTSL (0.55) | CTSLCTSKCTSBCTSSTACR1 | |
| SCHEMBL18930779 | 0.82 | CTSL (0.55) | CTSLCTSKCTSBCTSSTACR1 | |
| SCHEMBL18920632 | 0.82 | CTSL (0.55) | CTSLCTSKCTSBCTSSTACR1 | |
| SCHEMBL10706018 | 0.81 | CTSL (0.64) | CTSLCTSKCTSBCTSSTACR1 | |
| SCHEMBL7274495 | 0.80 | CTSS (0.60) | CTSLCTSKCTSBCTSSSCN9A | |
| SCHEMBL6329537 | 0.79 | CTSK (0.57) | CTSLCTSKCTSBCTSSTACR1 | |
| SCHEMBL31333474 | 0.78 | SYK (0.47) | — | |
| SCHEMBL31334655 | 0.78 | SYK (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | CTSL 230/4885CTSK 280/4885CTSB 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.